STL2 Antibody

ST2 Antibody in Immune Modulation

ST2 (IL-1RL1) is a member of the interleukin-1 receptor family, existing in membrane-bound (mST2) and soluble (sST2) forms. sST2 acts as a decoy receptor for IL-33, modulating Th2 immunity and regulatory T-cell (Treg) activity .

Key Findings

• GVHD Treatment: Anti-ST2 monoclonal antibody (CNT03914) reduced graft-versus-host disease (GVHD) severity in murine models by decreasing sST2-producing T cells and enhancing IL-33 bioavailability, leading to improved survival rates .

• Cardiac Transplant Rejection: Elevated sST2 levels (≥35 ng/mL) post-heart transplantation correlate with antibody-mediated rejection (32% vs. 4% in controls) .

Table 1: ST2 Antibody Applications

SSTR2 Antibody in Oncology and Neurobiology

Somatostatin receptor 2 (SSTR2) is a G-protein coupled receptor overexpressed in neuroendocrine tumors and medulloblastomas. Antibodies targeting its extracellular domain (e.g., clone UMB1) are widely used in diagnostics .

Research Highlights

• Western Blot Specificity: Anti-SSTR2 antibody ab134152 (clone UMB1) detects a 73 kDa band in human/mouse brain lysates, with validation across multiple cell lines (U937, MCF-7) .

• Immunohistochemistry: Demonstrates 95% sensitivity in pancreatic and neural tumors .

• Therapeutic Potential: Engineered LAABs (long-acting antibodies) like AstraZeneca’s AZD7442 use half-life extension technology for sustained activity .

Table 2: SSTR2 Antibody Performance

Comparative Analysis of ST2 vs. SSTR2 Antibodies

Mechanistic Insights

• ST2/IL-33 Axis: sST2 blockade with anti-ST2 mAb enhances IL-33 signaling, promoting Treg expansion and suppressing pathogenic Th1/Th17 cells .

• SSTR2 Signaling: Antibodies like ab134152 inhibit adenylyl cyclase and calcium channels, reducing hormone secretion in pancreatic cells .

Future Directions

• ST2: Phase III trials for LAAB combinations (e.g., AZD7442) in COVID-19 prophylaxis .

• SSTR2: Dual-targeting antibodies for combination therapies in neuroendocrine cancers .